SpaceX IPO could crown Elon Musk trillionaire, but his conduct is tied to mass deaths

Elon Musk's SpaceX IPO will probably make him the richest person ever to walk the planet, The Verge reports. That is the headline reality: the wealth thesis. But the story insists the moral and human cost cannot be separated from the capital story, because it ties Musk's actions from about a year ago to the deaths of hundreds of thousands of people, done knowingly.

In other words, the question for executives and boards is not just “how big could the payoff be?” It is “what are you underwriting when the market cheers the payout?” The Verge characterizes Musk as a figure whose “horrible personal conduct” could fill multiple books, then zeroes in on one fact it says stands out: a year ago, Musk's actions directly led to the deaths of hundreds of thousands of people. The report portrays it as not only knowing, but also “gleefully.” That is the kind of framing that changes how stakeholders interpret legitimacy, risk, and brand endurance.

Then the story widens to the policy machine, because money and influence do not operate in a vacuum. In the first months of President Donald Trump's second term, the Musk-led Department of Government Efficiency (DOGE) “destroyed the US Agency for International Development,” The Verge says. USAID’s mission, as described in the report, is to be a boon to public health around the globe. This part matters because it ties Musk’s orbit to institutional capacity. When you dismantle an agency built for international public health, the downstream effects are not limited to budgets. They can cascade into preparedness, funding continuity, and the ability to respond to health crises.

From an incentives standpoint, think of this as two parallel markets: the capital markets that may reward SpaceX with a valuation that accelerates Musk’s personal wealth, and the governance markets where decisions about federal agencies can reshape global health outcomes. Boards and investors often model the first market very precisely, especially around IPO timing and liquidity. The second market is harder to quantify and politically noisier. But The Verge is basically arguing you cannot treat the second market as “outside the deal.” If the political apparatus you are influencing materially reduces the resources of an agency like USAID, then the “risk” is not just reputational. It is structural.

Regulatory and institutional background helps explain why that distinction matters. Agencies like USAID sit at the intersection of public health delivery and government legitimacy. They typically serve as conduits for programs that can take years to build and may be difficult to replicate quickly after disruption. The Verge’s report, by highlighting the DOGE-linked destruction of USAID “in the first months” of the second term, implies a fast timeline from political decision to operational damage. When changes are abrupt, the lag between policy and measurable outcomes is often where executives get blindsided. The report’s claim that Musk's actions “directly led” to deaths of hundreds of thousands of people reinforces the idea that lag can still mean lethal consequences.

There is also a governance angle about who benefits when influence is concentrated. If DOGE is Musk-led and if that same influence sits close to SpaceX’s path to an IPO, then capital formation and state power are drawing closer. That is the kind of setup that can concentrate both upside and scrutiny. Even if different teams handle different domains, outsiders do not experience them that way. They see the same figure, the same orbit, and the same outcomes, then they ask whether board oversight and risk management were strong enough to account for real-world impact.

So what should decision-makers take from this? The Verge is essentially telling a story where the market could be rewarding a company while the broader societal costs attached to its founder’s conduct are severe. That puts executives and boards in a tight spot: you cannot ignore the financial gravity of an IPO that may place a person into “the world's first trillionaire” territory, but you also cannot pretend governance decisions are separate from human outcomes. The strategic stakes for peers are simple and uncomfortable. If a founder’s actions can be linked, in a reporting account, to catastrophic deaths and the dismantling of a global public health mission, then stakeholder expectations for diligence, oversight, and contingency planning will rise. And the reputational and political risk surface grows larger at the exact moment the valuation story gets louder.